

MARKSANS PHARMA LIMITED

Regd. Office: 601-622, Chintamani Plaza, Mohan Studio Compd, A.K.Road, Andheri (East), Mumbai-400099
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2007

Sr. No.	PARTICULARS	(Rs. In lacs)				(Rs. In lacs)
		Quarter ended		Twelve months ended		Year ended
		31st March 07 (UNAUDITED)	31st March 06 (UNAUDITED)	31st March 07 (UNAUDITED)	31st March 06 (AUDITED)	31st March 06 (AUDITED)
1	Net sales /Income from Operatio	2,668.71	4,502.10	24,078.70	29,185.45	29,185.45
2	Other Income	76.71	258.88	956.87	471.17	471.17
3	Total Expenditure	3,618.30	4,188.26	22,174.50	24,685.36	24,685.36
	-(Increase) /Decrease in Stock in	(3,109.36)	(1,541.11)	(4,001.87)	(2,355.44)	(2,355.44)
	-Consumption of Raw Material	4,575.10	4,618.21	20,419.31	22,648.37	22,648.37
	-Staff Cost	478.69	360.65	1,285.49	947.11	947.11
	-Other Expenditure	1,673.86	750.51	4,471.57	3,445.32	3,445.32
4	Interest	333.89	233.29	1,150.39	1,035.08	1,035.08
5	Depreciation	(6.91)	106.64	746.18	803.98	803.98
6	Profit/(Loss) before Ta	(1,199.86)	232.79	964.50	3,132.20	3,132.20
7	Provision for Taxation	(264.23)	218.24	132.86	814.24	814.24
8	Net Profit /(Loss)	(935.63)	14.55	831.65	2,317.96	2,317.96
9	Add/Less :Short(Exess) provision	(158.79)	-	(158.79)	29.53	29.53
	Prior period expenses	-	-	-	-	-
10	Net Profit/(after extra ordinary ite	(776.84)	14.55	990.44	2,288.43	2,288.43
11	Paid up Equity Share Capital (Face value Rs. 10 per share)	3,594.06	3,594.06	3,594.06	3,594.06	3,594.06
12	Reserves and Surplus (Excluding Revaluation Reserve)	-	-	-	-	-
13	Basic and Diluted EPS for the pe (Not annualised)	(2.16)	0.04	2.76	6.37	6.37
14	Non -Promoter share holding					
	-Number of Shares	18,776,527	18,778,569	18776527	18,778,569	18,778,569
	-Percentage of Share holding	52.24%	52.25%	52.24%	52.25%	52.25%

Notes:

- The above results were taken on records at the meeting of the Audit committee held on 30-04-2007
- The details of investor complaints during the quarter is as under:
Opening Balance : NIL, Received & Resolved during the quarter : 3, Pending as on 31.03.07 : NIL
- The company will consider the effect of deferred tax asset/liability (AS- 22) in the audited accounts at the year end.
- Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.
- During the current year , companys API division faced severe pricing pressure for its products from China resulting into losses for the division.The company is in the process of launching new products to reduce its dependency on old products. The company has filed 'COS' and 'DMF's with the European and US health authorities for its API products and is awaiting their approval for the launch of products in those regulated markets.
- During the current year company has entered into a collaboration agreement for the joint development, filing and marketing of eleven generic Pharmaeutical products for the US market. the product list includes a mixture of off-patent and patent protected molecules with cumulative annual sales in the US of about USD 17 billion. Upon approval, Marksans will exclusively manufacture and market the products. The company is charging entire research & development costs to Profit & Loss account in the year of its incurrance, resulting into pressure on the bottomline of the company
- During the quarter, company has provided for provision for bad & doubtful debts of Rs 3 crores
- Above figures are on standalone basis and it does not include results of M/s Nova Pharmaceuticals Australasia PTY Ltd.

For MARKSANS PHARMA LIMITED

Place: Mumbai

Date: 30th April, 2007

MARK SALDANHA
Managing Director